The Market In 5 Minutes: Walgreens-Rite Aid, Personal Income And Trump's Executive Order

Below is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. Apply for daily AM access by clicking here or email minutes@benzinga.com.

Macro Focus

Futures for the Dow Jones Industrial Average tumbled 45 points to 19,969.00, while the Standard & Poor’s 500 index futures fell 5.75 points to 2,283.25. Futures for the Nasdaq 100 index declined 14.75 points to 5,147.75.

Oil prices traded mixed as Brent crude futures dropped 0.07 percent to trade at $55.48 per barrel, while US WTI crude futures also rose 0.13 percent to trade at $53.24 a barrel.

USA Personal Income (MoM) for Dec 0.30% vs 0.40% Est; Personal Spending (MoM) for Dec 0.50% vs 0.50% Est

  • The pending home sales index for December is schedule for release at 10:00 a.m. ET.

  • The Dallas Fed manufacturing index for January will be released at 10:30 a.m. ET.

  • The Treasury is set to auction 3-and 6-month bills at 11:30 a.m. ET.

BZ News Desk Focus

  • Booz Allen Hamilton (NYSE: BAH) Reports Q3 Adj. EPS $0.38 vs $0.40 Est., Sales $1.4B vs $1.37B Est.

Most of the Dow Jones Industrial Average components have already reported their recent earnings, but there are a few more taking their turns in the spotlight this week, including pharmaceutical giants Merck (NYSE: MRK) and Pfizer (NYSE: PFE). Wall Street consensus forecasts call for earnings that are smaller than a year ago from both companies.

Neurotrope (OTC: NTRPD), a clinical stage biopharmaceutical company, may have found through its drug Bryostatin a unique solution to addressing Alzheimer's, one of the last major diseases with no cure. Benzinga recently spoke with CEO Dr. Susanne Wilke, ahead of her appearance at the Noble Financial Annual Investor Conference on January 30.

Sell-Side Themes

The market is readying itself for a slew of semiconductor earnings this week that comes amid secular declines in PC and tablet markets along with a saturating global smartphone unit growth. Canaccord Genuity analyst Matthew Ramsay's checks point to a solid channel and operating outlook for most of the companies in his coverage universe. The analyst expects modest low- to mid-single-digit overall semiconductor growth.

SunTrust and Needham both downgraded Regulus Therapeutics (NASDAQ: RGLS) after the company reported the continuation of RG-101 clinical hold.

Sell-Side's Most Noteworthy Calls

  • Baird downgraded Himax Technologies (NASDAQ: HIMX) to Neutral.

  • Argus downgraded Dupont (NYSE: DD) to Hold.

  • Morgan Stanley upgraded Disney (NYSE: DIS) to Overweight.

  • Goldman Sachs upgraded NetApp (NASDAQ: NTAP) to Buy.

  • Barclays started Stanley Black & Decker (NYSE: SWK) at Overweight.